Peptide Library

Human study PLS-00064

Effects of empagliflozin and dapagliflozin on serum humanin, MOTS-c levels, nitrosative stress, and ferroptosis parameters in diabetic patients with heart failure.

Cross-sectional study · Not reported participants enrolled · not included in the assessments (wrong compound)

Version 1 · published November 7, 2026 · evidence through November 7, 2026 · research snapshot 2026.1.1 · methodology ev-1 · Automated assessment by AI (claude-opus-5-5 and claude-sonnet-5-5), not reviewed by a person.

Only the abstract was available. Essential methods may be missing, which limits what can be judged.

Reports of this study

Every publication, registration and abstract describing this one study. Participants are counted once.

  • Effects of empagliflozin and dapagliflozin on serum humanin, MOTS-c levels, nitrosative stress, and ferroptosis parameters in diabetic patients with heart failure.primary · European journal of pharmacology · 2024-08-23 · PMID 39182552 · DOI

Design and participants

Design
Cross-sectional study
Population
Adult diabetic patients with heart failure with reduced ejection fraction, about half using SGLT2 inhibitors, plus healthy controls
Conditions
Type 2 diabetes, Heart failure with reduced ejection fraction
Planned enrollment (registry)
Not reported
Enrolled
Not reported
Randomized
Not reported
Completed follow-up
Not reported

Intervention and comparator

What each group received. Related peptides, analogs and combinations are never treated as the compound itself.

    What the authors reported

    As stated in the sources. This is the authors’ account, not Peptide Library’s assessment.

    Adverse events

    None reported. That is not evidence of safety, and how safety was monitored isn’t described.

    The authors concluded (paraphrased): The authors conclude that SGLT2 inhibitors reduced nitrosative stress and ferroptosis markers and raised serum MOTS-c, but not humanin, in diabetic HFrEF patients. They suggest these mechanisms may underlie the drugs' cardioprotection.

    Peptide Library’s assessment

    An automated assessment, made by AI separately from the authors’ conclusions and not reviewed by a person. How risk of bias is assessed.

    Limitations

    • other: MOTS-c was not administered. It was only measured as an endogenous serum biomarker in response to SGLT2 inhibitors.
    • abstract only: Only the PubMed abstract is available. Methods, funding and conflicts are not described in the record.
    • inappropriate endpoint: MOTS-c was measured as an endogenous serum level, not given as an intervention, so the study cannot show effects of MOTS-c.

    No risk-of-bias assessment has been published for this study’s results.

    Claims this study informs

    Where each value comes from

    • author_conclusion: PMID 39182552, abstract (sentences 10-13) · extracted by AI (automated, not verified by a person) · abstract only
    • design: PMID 39182552, abstract (sentence 4) · extracted by AI (automated, not verified by a person) · abstract only
    • population: PMID 39182552, abstract (sentences 4-5) · extracted by AI (automated, not verified by a person) · abstract only

    • Version 1 · published November 7, 2026 · evidence through November 7, 2026 · research snapshot 2026.1.1 · methodology ev-1 · Automated assessment by AI (claude-opus-5-5 and claude-sonnet-5-5), not reviewed by a person.

    These assessments describe published research. Records marked automated were produced by AI under the published methodology and have not been reviewed by a person; they can contain errors. None of this is medical advice, not a statement about any product’s safety for human use, and not a regulatory approval. Peptide Library’s vendor and partner relationships play no part in them (editorial independence).